Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study

Clinical Therapeutics
Jonathan M MeyerAndrew Greenspan

Abstract

A major contributor to mortality inpatients with schizophrenia or schizoaffective disorder is cardiovascular disease, an important risk factor for which is the cluster of clinical abnormalities that define the metabolic syndrome (eg, abdominal/visceral obesity, hypertriglyceridemia, impaired glucose tolerance). The aim of this article was to examine the effects of switching from the antipsychotic olanzapine to risperidone on the prevalence of the metabolic syndrome in high-risk overweight or obese patients with schizophrenia or schizoaffective disorder. This post hoc analysis was based on data from a previous 2-phase, 20-week, multicenter (19 US sites), rater-blinded, open-label study. High-risk overweight or obese (body mass index [BMI], >26 kg/m(2)) patients aged 18 to 65 years with schizophrenia or schizoaffective disorder whose treatment was switched from olanzapine to risperidone were enrolled. Patients who entered the phase 1 switch from olanzapine to risperidone (6 weeks) and the phase 2 extension (14 weeks) were included in the assessment. The primary end point was the difference from baseline in the prevalence of the metabolic syndrome at week 20, determined using measurements of weight, BMI, waist circumference, and s...Continue Reading

References

Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Sep 9, 2000·Schizophrenia Research·U OsbyP Sparén
Nov 22, 2000·Schizophrenia Bulletin·L DixonA Lehman
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Jan 16, 2002·JAMA : the Journal of the American Medical Association·Earl S FordWilliam H Dietz
Feb 4, 2003·The American Journal of Psychiatry·Martina C M RyanJogin H Thakore
Mar 11, 2003·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·George KirovMichael J Owen
May 21, 2003·The Journal of Clinical Psychiatry·Tuula HeiskanenJukka Hintikka
Nov 19, 2003·Journal of Clinical Psychopharmacology·Peter J WeidenSteven J Romano
Feb 26, 2004·Obesity Research·UNKNOWN American Diabetes AssociationUNKNOWN North American Association for the Study of Obesity
Mar 9, 2004·The Journal of Clinical Psychiatry·UNKNOWN American Diabetes AssociationUNKNOWN North American Association for the Study of Obesity
Apr 2, 2004·The British Journal of Psychiatry. Supplement·Chris Bushe, Richard Holt
Aug 3, 2004·The American Journal of Psychiatry·Stephen R MarderSteven Shon
Sep 29, 2004·Diabetes Care·Earl S FordAli H Mokdad

❮ Previous
Next ❯

Citations

Jun 3, 2010·European Archives of Psychiatry and Clinical Neuroscience·M K YaziciS L Tokgözoğlu
Feb 4, 2009·Current Psychiatry Reports·John O BrooksOlya Krasnykh
Jun 1, 1982·Electroencephalography and Clinical Neurophysiology·J M FusterJ W Ashford
Jun 1, 1993·Electroencephalography and Clinical Neurophysiology·H L CohenH Begleiter
Apr 1, 1978·Pharmacology, Biochemistry, and Behavior·P E PennT K Li
Jun 1, 1980·Pharmacology, Biochemistry, and Behavior·R A BierleyR E Dustman
Jan 1, 1981·Pharmacology & Therapeutics·H Kalant, N Woo
Oct 22, 2013·Pharmacology, Biochemistry, and Behavior·Boris Tabakoff, Paula L Hoffman
Jul 14, 2007·International Journal of Clinical Practice·A TschonerC F Ebenbichler
Nov 28, 2012·Therapeutic Advances in Endocrinology and Metabolism·Evangelos Papanastasiou
Jul 26, 2008·Postgraduate Medicine·Leslie Citrome, Betty Vreeland
Oct 12, 2013·Postgraduate Medicine·Mehrul Hasnain, W Victor R Vieweg
Apr 10, 2008·Current Medical Research and Opinion·Douglas E FariesBruce J Kinon
Aug 28, 2007·The Psychiatric Clinics of North America·Deanna L KellyRobert R Conley
Mar 24, 2007·Metabolism: Clinical and Experimental·Tanja BergmannAndreas Weimann
Jan 13, 2009·Acta Psychiatrica Scandinavica·J M Meyer, S M Stahl
Dec 20, 2011·Early Intervention in Psychiatry·Sandeep GroverDeepak Ghormode
Oct 1, 2005·International Review of Psychiatry·Jonathan MeyerGilbert J L'Italien
May 7, 2013·Expert Opinion on Drug Metabolism & Toxicology·Vidya PereraAndrew J McLachlan
Mar 10, 2015·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Andrea MurruEduard Vieta
Jan 25, 2006·Journal of Psychiatric Practice·Jonathan MeyerDonna Wirshing
Jan 27, 2007·The Cochrane Database of Systematic Reviews·G FaulknerG Remington
May 7, 2019·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Taishiro KishimotoChristoph U Correll
Mar 20, 2010·The Cochrane Database of Systematic Reviews·Katja KomossaStefan Leucht
Sep 28, 2010·Bipolar Disorders·Mani N PavuluriJohn A Sweeney
Feb 1, 2013·Clinical Schizophrenia & Related Psychoses·Jeffrey Charles FetterAlan I Green
Jul 1, 2010·Expert Review of Neurotherapeutics·Lawrence Maayan, Christoph U Correll
Nov 7, 2007·CNS Spectrums·Christoph U Correll
Aug 29, 2006·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Guy Faulkner, Tony A Cohn

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.